| 31943796 |
Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer
Uchibori, K,
Yanagitani, N,
Tsukahara, M,
Okubo, K,
Nishio, M,
Seto, Y,
Okada, K,
Takahashi, K,
Oh-Hara, T,
Uematsu, S,
Fujita, N,
Katayama, R
|
Thorac Cancer |
2020 |
| 31616196 |
TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations
Patel, NR,
Khurshid, H,
Ali, SM,
Aswad, BI,
Resnick, MB,
Yakirevich, E,
Ouseph, MM,
Taber, A,
Madison, R
|
Lung Cancer (Auckl) |
2019 |
| 29650534 |
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
Mino-Kenudson, M,
Friboulet, L,
Benes, CH,
Engelman, JA,
Yoda, S,
Gainor, JF,
Dardaei, L,
Iafrate, AJ,
Heist, RS,
Shaw, AT,
Dagogo-Jack, I,
Langenbucher, A,
Burke, BJ,
Hata, AN,
Ferris, LA,
Timonina, D,
Johnson, TW,
Hubbeling, H,
Timofeevski, S,
Lawrence, MS,
Kattermann, KE,
Lin, JJ,
Prutisto-Chang, K,
Riley, AK,
Lennerz, JK
|
Cancer Discov |
2018 |
